A Phase 1, Randomized, Double-blind, Third-party Open, Placebo-controlled Study To Evaluate The Safety, Tolerability, And Pharmacokinetics After Multiple Oral Doses Of Pf-06700841 In Healthy Japanese Subjects
Phase of Trial: Phase I
Latest Information Update: 27 Oct 2017
At a glance
- Drugs PF 6700841 (Primary)
- Indications Alopecia areata; Plaque psoriasis; Ulcerative colitis
- Focus Adverse reactions
- Sponsors Pfizer
- 23 Oct 2017 Status changed from recruiting to completed.
- 25 Sep 2017 Planned End Date changed from 13 Oct 2017 to 12 Oct 2017.
- 04 Sep 2017 Planned End Date changed from 12 Oct 2017 to 13 Oct 2017.